BioNano Genomics, Inc. (BNGO) Reports Q4 Net Loss of $29.5M
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Bionano Genomics (BNGO) PT Lowered to $8 at Ladenburg Thalmann
March 2, 2022 7:45 AM ESTLadenburg Thalmann analyst Jeffrey Cohen lowered the price target on Bionano Genomics (NASDAQ: BNGO) to $8.00 (from $9.50) while maintaining a Buy rating following results.
The analyst commented, "Bionano announced Q4- and FY-2021 financial results and held a conference call to discuss. For the... More
